Copanlisib (BAY80-6946)
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell
Trial Timeline
Aug 24, 2015 → Aug 31, 2016
NCT ID
NCT02455297About Copanlisib (BAY80-6946)
Copanlisib (BAY80-6946) is a phase 2 stage product being developed by Bayer for Lymphoma, Mantle-Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT02455297. Target conditions include Lymphoma, Mantle-Cell.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05217914 | Pre-clinical | Completed |
| NCT02455297 | Phase 2 | Terminated |
| NCT02342665 | Phase 1/2 | Completed |
| NCT02155582 | Phase 1 | Completed |
| NCT02119221 | Phase 1 | Completed |
Competing Products
20 competing products in Lymphoma, Mantle-Cell